Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (vol 22, pg 489, 2021)

被引：0
|
作者：
Rugo, H. S.
Lerebours, F.
Ciruelos, E.
机构：
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E184 / E184
页数：1
相关论文
共 50 条
  • [1] Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (Expression of Concern of Vol 22, Pg 489, 2021)
    不详
    LANCET ONCOLOGY, 2024, 25 (02): : e42 - e42
  • [2] Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
    Rugo, Hope S.
    Lerebours, Florence
    Ciruelos, Eva
    Drullinsky, Pamela
    Ruiz-Borrego, Manuel
    Neven, Patrick
    Park, Yeon Hee
    Prat, Aleix
    Bachelot, Thomas
    Juric, Dejan
    Turner, Nicholas
    Sophos, Nickolas
    Zarate, Juan Pablo
    Arce, Christina
    Shen, Yu-Ming
    Turner, Stuart
    Kanakamedala, Hemanth
    Hsu, Wei-Chun
    Chia, Stephen
    LANCET ONCOLOGY, 2021, 22 (04): : 489 - 498
  • [3] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    Roufai, D. Bello
    Goncalves, A.
    Rouge, T. De La Motte
    Akla, S.
    Blonz, C.
    Grenier, J.
    Gligorov, J.
    Saghatchian, M.
    Bailleux, C.
    Simon, H.
    Desmoulins, I
    Tharin, Z.
    Renaud, E.
    Bertho, M.
    Benderra, M-A
    Delaloge, S.
    Robert, L.
    Cottu, P.
    Pierga, J. Y.
    Loirat, D.
    Bertucci, A.
    Renouf, B.
    Bidard, F. C.
    Lerebours, F.
    ONCOGENE, 2023, 42 (23) : 1951 - 1956
  • [4] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    D. Bello Roufai
    A. Gonçalves
    T. De La Motte Rouge
    S. Akla
    C. Blonz
    J. Grenier
    J. Gligorov
    M. Saghatchian
    C. Bailleux
    H. Simon
    I. Desmoulins
    Z. Tharin
    E. Renaud
    M. Bertho
    M-A Benderra
    S. Delaloge
    L. Robert
    P. Cottu
    J. Y. Pierga
    D. Loirat
    A. Bertucci
    B. Renouf
    F. C. Bidard
    F. Lerebours
    Oncogene, 2023, 42 : 1951 - 1956
  • [5] Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    D. Bello Roufai
    A. Gonçalves
    T. De La Motte Rouge
    S. Akla
    C. Blonz
    J. Grenier
    J. Gligorov
    M. Saghatchian
    C. Bailleux
    H. Simon
    I. Desmoulins
    Z. Tharin
    E. Renaud
    M. Bertho
    M-A Benderra
    S. Delaloge
    L. Robert
    P. Cottu
    J. Y. Pierga
    D. Loirat
    A. Bertucci
    B. Renouf
    F. C. Bidard
    F. Lerebours
    Oncogene, 2023, 42 : 1417 - 1417
  • [6] Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study
    Chia, Stephen
    Neven, Patrick
    Ciruelos, Eva M.
    Lerebours, Florence
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Prat, Aleix
    Park, Yeon Hee
    Juric, Dejan
    Turner, Nicholas C.
    Chattar, Yogesh
    Patino, Heather
    Akdere, Murat
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Alpelisib plus letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
    Rugo, Hope S.
    Lerebours, Florence
    Juric, Dejan
    Turner, Nicholas
    Chia, Stephen
    Drullinsky, Pamela
    Prat, Aleix
    Villanueva Vazquez, Rafael
    Akdere, Murat
    Arce, Christina
    Shen, Yu-Ming
    Ciruelos, Eva
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Alpelisib plus fulvestrant in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A
    Ciruelos, Eva M.
    Lerebours, Florence
    Rugo, Hope S.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Prat, Aleix
    Bachelot, Thomas
    Neven, Patrick
    Park, Yeon Hee
    Turner, Nicholas
    Juric, Dejan
    Gu, Ennan
    Arce, Christina H.
    Akdere, Murat
    Chia, Stephen
    CANCER RESEARCH, 2022, 82 (04)
  • [9] Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S15 - S16
  • [10] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
    Andre, F.
    Ciruelos, E. M.
    Juric, D.
    Loibl, S.
    Campone, M.
    Mayer, I. A.
    Rubovszky, G.
    Yamashita, T.
    Kaufman, B.
    Lu, Y-S
    Inoue, K.
    Papai, Z.
    Takahashi, M.
    Ghaznawi, F.
    Mills, D.
    Kaper, M.
    Miller, M.
    Conte, P. F.
    Iwata, H.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 208 - 217
12345